<DOC>
	<DOCNO>NCT02016872</DOCNO>
	<brief_summary>The purpose study help researcher investigate new image agent name 18F-FMISO predict patient lung cancer respond standard therapy , well whether disease reoccur future . The study also investigate whether 18F-FDG PET scan middle radiation treatment predict lung cancer respond standard therapy . Information obtain study may help doctor design future study may target tumor area respond therapy may likely reoccur future .</brief_summary>
	<brief_title>Prognostic Value Tumor Hypoxia , Measured 18F-FMISO Breath Hold PET/CT , Non-Small-Cell-Lung Cancer ( NSCLC ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Anoxia</mesh_term>
	<mesh_term>Misonidazole</mesh_term>
	<criteria>Pathologic confirmation NSCLC MSKCC No prior treatment diagnosis NSCLC Patient treat neoadjuvant chemotherapy ( 35 patient total ) patient treat definitive RT , sequential chemoRT , concurrent chemoRT ( minimum dose 50 Gy 25 fraction ) ( 25 patient total ) Tumor must measure ≥ 2cm CT Age ≥ 18 year Ability hold breath 10 second . Karnofsky performance status ≥ 70 % Women childbearing age must negative blood pregnancy test Women pregnant breastfeeding Severe diabetes ( fast Blood Glucose &gt; 200 mg/dl )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PET/CT</keyword>
	<keyword>18F-FMISO</keyword>
	<keyword>tumor hypoxia</keyword>
	<keyword>13-186</keyword>
</DOC>